<DOC>
	<DOCNO>NCT01820585</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled , parallel-group , multicentre , multinational , Phase II study 528 subject pain due Fibromyalgia syndrome ( FMS ) . Subjects randomise 1:1:1:1 ratio receive placebo , Eslicarbazepine acetate ( ESL ) 400 mg daily ( QD ) , ESL 800 mg QD ESL 1200 mg QD . The study carry follow .</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate Therapy Subjects With Fibromyalgia</brief_title>
	<detailed_description>This double-blind , randomise , placebo-controlled , parallel-group , multicentre , multinational , Phase II study 528 subject pain due FMS . Subjects randomise 1:1:1:1 ratio receive placebo , ESL 400 mg daily ( QD ) , ESL 800 mg QD ESL 1200 mg QD . The study carry follow : Screening Visit ( Visit [ V ] 1 ) : After complete screening procedure V1 , eligible subject begin 2 week Baseline Period . Baseline Period ( 2 week ) : Subjects discontinue take prohibited medication V1 ( begin washout period ) . Subjects taper discontinued medication . Washout complete Day -7 ( 7 day V2 ) . Subjects refrain take pain medication prohibit medication ( except rescue medication ) throughout study . During Baseline Period , subject use subject diary complete diary pain assessment 0-10 numeric pain rating scale ( NPRS ) record information rescue medication daily awaken . Titration Period ( 1 week ) : Upon complete Baseline Period , subject return study centre V2 ( Randomisation Visit , Day 1 ) . At V2 , subject , complete least 4 subject diary pain assessment satisfactorily within past 7 day , average pain score ≥4 ≤9 continue meet study entry criterion , randomly assign 1 4 treatment group . During 1-week Titration Period , subject randomise ESL 400 mg QD ESL 800 mg QD treatment group receive ESL 400 mg QD ; subject randomise ESL 1200 mg QD treatment group receive ESL 600 mg QD ; subject assign placebo treatment receive placebo QD . Maintenance Period ( 12 week ) : Starting V3 , subject assign treatment ESL receive full dosage regimens QD ; subject assign placebo treatment receive placebo QD . During Maintenance Period , subject visit every 4 week . Follow-up Period ( 2 week ) : Approximately 2 week take last dose study medication , subject return study centre Follow-up Visit underwent end-of-study evaluation .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Subject male female , 18 year age older ( accord Amendment # 1 Czech Republic [ 24 MARCH 2009 ] : 18 65 year age ) . Subject able willing provide write informed consent participate study opportunity review Subject Information Sheet Informed Consent Form . Subject meet American College Rheumatology ( ACR ) 1990 diagnostic criterion FMS ( widespread pain least 3 month pain least 11 18 tender point ) ( accord Amendment # 1 Czech Republic [ 24 MARCH 2009 ] : subject 's current FMS treatment either inefficacious intolerable side effect ) . Subject willing able understand comply study requirement , judgment investigator . Subject negative result urine test drug abuse V1 ( Screening Visit ) , except medications/drugs report subject Screening Visit . Subject use allowable nonpharmacological therapy stable least 4 week prior V1 ( Screening Visit ) would maintain stable regimen throughout study . Female subject surgically sterile ( i.e . bilateral tubal ligation , bilateral oophorectomy hysterectomy ) least 2 year postmenopausal , childbearing potential , sexually abstinent agree use medically acceptable nonhormonal method contraception Addendum accord Amendment # 1 Czech Republic [ 24 MARCH 2009 ] : Hormonal contraceptive acceptable contraceptive method study . However , intake forbidden throughout study . Addendum accord Amendment # 1 Spain [ 19 JANUARY 2009 ] United Kingdom [ 24 MARCH 2009 ] : Male subject sexually abstinent agree use reliable contraceptive method ( i.e . doublebarrier method : 1 male barrier [ male condom ] plus 1 female barrier method [ female condom , spermicide intrauterine device ] . This mandatory even sexually active men sterilise . Subject negative urine test drug abuse . The subject complete least 4 subject diary pain assessment satisfactorily within past 7 day prior V2 average pain score ≥4 ≤9 . Subject known hypersensitivity ESL carboxamide derivative ( e.g . oxcarbazepine , carbamazepine ) excipients . Subject history current active malignancy except follow : basal cell carcinoma treat ; malignancy successfully treat recurrence within 5 year V1 ( Screening Visit ) . Subject severe hepatic , renal , respiratory , hematologic immunologic illness , unstable cardiovascular disease medical psychiatric condition , judgment investigator , make subject inappropriate entry study . Subject second thirddegree atrioventricular blockade correct pacemaker clinically significant abnormality 12lead ECG determine investigator . Subject history illicit drug alcohol abuse within 2 year V1 ( Screening Visit ) . Subject receive investigational drug ( medical device ) within 3 month Screening currently participate another study investigational drug ( medical device ) . Subject pregnant nursing . Subject employee investigator study centre , direct involvement propose study study direction investigator study centre family member employee investigator . Subject following : inflammatory muscle rheumatologic disease FMS ; multiple sclerosis ; active infection ; untreated endocrine disorder ; uncontrolled hypo hyperthyroidism type . Subjects whose pain due primarily FMS . Subject underwent tender point injection within 30 day V1 ( Screening Visit ) and/or subject unwilling refrain tender point injection throughout study . Subject white blood cell ( WBC ) count &lt; 2.5 × 109/L , neutrophil count &lt; 1.5 × 109/L , Na+ &lt; 125 mmol/L alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥2 × upper limit normal V1 ( Screening Visit ) clinically relevant laboratory abnormality , investigator 's opinion , could compromise subject 's safety . Subject abnormal value antinuclear antibody ( ANA &gt; 1/160 ) rheumatoid factor ( RF &gt; 15 IU/mL ) V1 ( Screening Visit ) . After approval global amendment respective country , limit ANA change ≥1/160 . Subject abnormal Westergren erythrocyte sedimentation rate ( ESR ) V1 ( Screening Visit ) ( ESR &gt; 40 mm/h ) . Subject creatinine clearance ( CLCr ) low 60 mL/min Screening . Subject Montgomery Åsberg Depression Rating Scale ( MADRS ) total score ≥35 score 4 6 question 10 MADRS V1 ( Screening Visit ) . Subject use prohibit concomitant medication 2week Baseline Period use fluoxetine 30 day V1 ( Screening Visit ) . Subject use opiate every day 30 day V1 ( Screening Visit ) control pain related FMS . Exclusion criterion V2 : Subject MADRS total score ≥35 score 4 6 question 10 MADRS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>Eslicarbazepine acetate ( BIA 2-093 )</keyword>
	<keyword>ESL</keyword>
</DOC>